Immunome Inc to buy a set of antibody-related assets and materials from Atreca Inc.
Immunome Inc. (Nasdaq: IMNM), a biotechnology company that develops innovative and superior targeted cancer therapies, announced today that it has signed a definitive agreement to buy a set of antibody-related assets and materials from Atreca, Inc. (Nasdaq: BCEL). According to…